jzs-10790

In vitro Cytotoxic Activity of Some Fecal Filtrates

Karokh Ali Khdir1 & Bahrouz Mahmood Al-Jaff1

1Biology Department, College of Education, University of Sulaimani, Sulaimani, Kurdistan Region- Iraq

Original: 3 January 2020       Revised: 25 February 2020     Accepted: 5 April 2020        Published online: 20 June 2020  

Doi Link; https://doi.org/10.17656/jzs.10790

Abstract

Animal feces have been studied and recognized as a crucial resource for exploring and discovering new novel bioactive compounds produced by host, microbiota, or host- microbiota interaction that may have therapeutic importance. To investigate the cytotoxic effect of human (healthy and colorectal cancer), dog, and cow fecal filtrates that serves as natural bioreactors. The cytotoxic activity was calculated as inhibitory concentration (IC50) based on the percentage of % viability using MTT 3-(4, 5-dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) assay for 4 crude cell-free fecal filtrates and their Sephadex G100 fractions in vitro against HeLa human cervical cancer cell line. The optical densities (OD) of the fractions were checked at wavelength of 280 nm and considered in the assay rather than cytotoxic active compound concentrations.  Cytotoxic activity of each crude fecal filtrate appeared to be dose-dependent (P<0.001) and less active than 40-400 μg/ml 5-flourouracil (5-FU). IC50 for dog, cow, healthy human, colorectal fecal filtrates, and 5-FU were 442.64 ± 23.29, 1265 ± 35.8, 1715 ± 56.9, 400.76 ± 32 and 134.33 ± 3.29 μg/ml respectively. Out of 11 dog fecal filtrate fractions, 4 fractions (F4, F5, F6 and F7) were within IC50 range. Out of 10 cow fecal filtrate fractions, 3 fractions (F3, F5 and F6) were within IC50 range. Out of 11 healthy human fecal filtrate fractions, 2 fractions (F3 and F4) were within IC50 range. Out of 12 colorectal fecal filtrate fractions; 4 fractions (F2, F3, F4 and F6) were within IC50 range against HeLa cells. The crude fecal filtrates and their fractions were with apparent cytotoxic activity showed that the colorectal patients and dogs’ fecal filtrates have higher cytotoxic activity followed by cows and then the healthy humans. This step could be a start for identifying compounds responsible for cytotoxic activity in hope to explore new medicine with therapeutic activity against cancer.

Key Words: Fecal filtrate, Mixed fermentation, Cytotoxic activity, Cervical cancer  cells

 References

[1] Mann, J., “Natural products in cancer chemotherapy: past, present and future.” Nature Reviews Cancer. Vol. 2, No. 2, pp.143-148. (2002).

[2] Rose, C., et al., "The characterization of feces and urine: a review of the literature to inform advanced treatment technology.” Critical reviews in environmental science and technology. Vol. 45, No. 17, pp. 1827-1879. (2015).

[3] Heaton, K.W., et al., "Defecation frequency and timing, and stool form in the general population: a prospective study". Gut. Vol. 33, No. 6, pp. 818-824. (1992).

[4] Simpson, J.M., et al., "Characterization of fecal bacterial populations in canines: effects of age, breed and dietary fiber". Microbial ecology. Vol. 44, No. 2, pp. 186-197. (2002).

[5] Achour, L., et al., "Faecal bacterial mass and energetic losses in healthy humans and patients with a short bowel syndrome". European journal of clinical nutrition. Vol. 61, No. 2, pp. 233. (2007).

[6] Leser, T.D. and L. Mølbak, "Better living through microbial action: the benefits of the mammalian gastrointestinal microbiota on the host". Environmental microbiology. Vol. 11, No 9, pp. 2194-2206. (2009).

[7] Liang, C., K.C. Das, and R.W. McClendon, "The influence of temperature and moisture contents regimes on the aerobic microbial activity of a biosolids composting blend". Bioresource technology. Vol. 86, No. 2, pp. 131-137. (2003).

[8] Guendouz, J., et al., "High-solids anaerobic digestion: comparison of three pilot scales". Water Science and Technology. Vol. 58, No. 9, pp. 1757-1763. (2008).

[9] Aroniadis, O.C. and L.J. Brandt, "Fecal microbiota transplantation: past, present and future". Current opinion in gastroenterology. Vol. 29, No. 1, pp. 79-84. (2013).

[10] Ryan, R.W., I.R. Kwasnik, and R.C. Tilton, "Rapid detection of Clostridium difficile toxin in human feces". Journal of clinical microbiology. Vol.12, No. 6, pp. 776-779. (1980).

[11] Cover, T.L., G.I. Perez-Perez, and M.J Blaser, "Evaluation of cytotoxic activity in fecal filtrates from patients with Campylobacter jejuni or Campylobacter coli enteritis". FEMS microbiology letters. Vol. 70, No. 3, pp. 301-304. (1990).

[12] Ferreira, C.E.. V. Nakano and M.L. Avila-Campos, "Cytotoxicity and antimicrobial susceptibility of Clostridium difficile isolated from hospitalized children with acute diarrhea". Anaerobe. Vol.10, No. 3, pp. 171-177. (2004).

[13] Gullikson, G.W., W.S. Cline. V. Lorenzsonn, L. Benz, W.A. Olsen, and P. Bass, "Effects of anionic surfactants on hamster small intestinal membrane structure and function: relationship to surface activity". Gastroenterology. Vol. 73, No.3, pp. 501-511. (1977).

[14] Rafter, J.J., P. Child, A.M. Anderson, R. Alder. V. Eng, and W.R. Bruce, "Cellular toxicity of fecal water depends on diet". The American journal of clinical nutrition. Vol. 45, No. 3, pp. 559-563. (1987).

[15] Davis, C.D. and J.A. Milner, "Gastrointestinal microflora, food components and colon cancer prevention". The Journal of nutritional biochemistry. Vol. 20, No. 10, pp. 743-752. (2009).

[16] Mahmud, A., "An investigation of the relationship between dietary fiber, fecal bacterial composition, and colon cancer." Ph.D. dissertation, Carleton University, Ottawa, Canada. (2012).

[17] Ley, R.E., et al., "Evolution of mammals and their gut microbes". Science. Vol. 320, No. 5883, pp. 1647-1651. (2008).

[18] Arnison, P.G., et al., "Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature". Natural product reports. Vol. 30, No. 1, pp. 108-160. (2013).

[19] Donia, M.S., et al., "A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics". Cell. Vol. 158, No. 6, pp. 1402-1414. (2014).

[20] Dan. V.M. and R. Sanawar, "Anticancer agents from microbes". In Bioresources and Bioprocess in Biotechnology. pp. 171-184. (2017).

[21] Supaphol, S., et al., "Microbial community dynamics in mesophilic anaerobic co-digestion of mixed waste". Bioresource technology. Vol. 102, No. 5, pp. 4021-4027. (2011).

[22] Gomathi, M. and P. Thangaraj, "A computer aided diagnosis system for lung cancer detection using support vector machine". American Journal of Applied Sciences. Vol. 7, No. 12, pp. 1532. (2010).

[23] Bray, F., et al., "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA: a cancer journal for clinicians. Vol. 68, No. 6, pp. 394-424. (2018).

[24] Rutledge, P.J. and G.L. Challis, "Discovery of microbial natural products by activation of silent biosynthetic gene clusters". Nature reviews microbiology. Vol. 13, No. 8, pp. 509-523. (2015).

[25] Newman, D.J., G.M. Cragg, and K.M. Snader, "The influence of natural products upon drug discovery". Natural product reports. Vol. 17, No. 3, pp. 215-234. (2000).

[26] Pettit, R.K., "Mixed fermentation for natural product drug discovery". Applied microbiology and biotechnology. Vol. 83, No. 1, pp. 19-25. (2009).

[27] Marmann, A., et al., "Co-cultivation—a powerful emerging tool for enhancing the chemical diversity of microorganisms". Marine drugs. Vol. 12, No. 2, pp. 1043-1065. (2014).

[28] Zhou, Y., et al., "Alkaloids from the Sponge‐Associated Fungus Aspergillus spp". European Journal of Organic Chemistry. Vol. 2013, No. 5, pp. 894-906. (2013).

[29] Louie, T. and P.C. Adams, "Nature’s therapy for recurrent Clostridium difficile diarrhea". Canadian Journal of Gastroenterology and Hepatology. Vol. 22, No. 5, pp. 455-456. (2008).

[30] Lozupone, C.A., et al., "Diversity, stability and resilience of the human gut microbiota". Nature. Vol. 489, No, 7415, pp. 220. (2012).

[31] Malla, S., et al., "Limitations in doxorubicin production from Streptomyces peucetius". Microbiological research. Vol. 165, No. 5, pp. 427-435. (2010).

[32] Encalada, M.A., et al., "Anti-proliferative effect of Melissa officinalis on human colon cancer cell line". Plant foods for human nutrition. Vol. 66, No. 4, pp. 328-334. (2011).

[33] Senthilraja, P. and K. Kathiresan, "In vitro cytotoxicity MTT assay in Vero, HepG2 and MCF-7 cell lines study of Marine Yeast". Journal of Applied Pharmaceutical Science. Vol. 5, No. 3, pp. 80-84. (2015).

[34] Ó’Fágáin, C., P.M. Cummins, and B.F. O’Connor, "Gel-filtration chromatography". In Protein Chromatography. Humana Press. pp.  25-33. (2011).

[35] Healthcare, G.E., "Size exclusion chromatography: Principles and Methods". GE Healthcare. Handbooks, pp. 139. (2012).

[36] Da Rocha, A.B., R.M. Lopes, and G. Schwartsmann, "Natural products in anticancer therapy". Current opinion in pharmacology. Vol. 1, No. 4, pp. 364-369. (2001).

[37] Frey, J.C., et al., "Fecal bacterial diversity in a wild gorilla". Applied and. Environmental Microbiology. Vol. 72, No. 5, pp. 3788-3792. (2006).

[38] Donaldson, G.P., S.M. Lee, and S.K. Mazmanian, "Gut biogeography of the bacterial microbiota". Nature Reviews Microbiology. Vol. 14, No. 1, pp. 20. (2016).

[39] Rowland, I., et al., "Gut microbiota functions: metabolism of nutrients and other food components". European journal of nutrition. Vol. 57, No. 1, pp. 1-24. (2018).

[40] Nützmann, H.W., et al., "Bacteria-induced natural product formation in the fungus Aspergillus nidulans requires Saga/Ada-mediated histone acetylation". Proceedings of the National Academy of Sciences. Vol. 108, No. 34, pp. 14282-14287. (2011).

[41] Salmon, I. and A.T. Bull, "Mixed-culture fermentations in industrial microbiology". Current perspectives in microbial ecology, pp. 656–662. (1984).

[42] Degenkolb, T., et al., "Formation of new lipoaminopeptides, acremostatins A, B, and C, by co-cultivation of Acremonium sp. Tbp-5 and Mycogone rosea DSM 12973". Bioscience, biotechnology, and biochemistry. Vol. 66, No. 4, pp. 883-886. (2002).

[43] Knight. V., et al., "Diversifying microbial natural products for drug discovery". Applied Microbiology and Biotechnology. Vol. 62, No. 5-6, pp. 446-458. (2003).

[44] Zwielehner, J., et al., "Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting". PloS one. Vol.  6, No. 12, p. e28654. (2011).

[45] Nourissat, A., et al., "Relationship between nutritional status and quality of life in patients with cancer". European journal of cancer. Vol. 44, No. 9, pp. 1238-1242. (2008).

[46] Netzker, T., et al., "Microbial communication leading to the activation of silent fungal secondary metabolite gene clusters". Frontiers in microbiology. Vol. 6, pp. 299. (2015).

[47] Oh, D.C., et al., "Libertellenones A–D: Induction of cytotoxic diterpenoid biosynthesis by marine microbial competition". Bioorganic & medicinal chemistry. Vol. 13, No. 17, pp. 5267-5273. (2005).

[48] Zuck, K.M., S. Shipley, and D.J. Newman, "Induced production of N-formyl alkaloids from Aspergillus fumigatus by co-culture with Streptomyces peucetius". Journal of natural products. Vol. 74, No. 7, pp. 1653-1657. (2011).

[49] Pettit, R.K., et al., "Isolation of human cancer cell growth inhibitory, antimicrobial lateritin from a mixed fungal culture". Planta medica. Vol. 76, No. 05, pp. 500-501. (2010).

[50] Kennedy, E., et al., "Cytotoxic effects of children's faeces: relation to diarrhoea due to Clostridium difficile and other enteric pathogens". Annals of tropical paediatrics. Vol. 11, No. 2, pp. 107-112. (1991).

[51] Muegge, B.D., et al., "Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans". Science. Vol. 332, No. 6032, pp. 970-974. (2011).

[52] Doroghazi, J.R., et al., "A roadmap for natural product discovery based on large-scale genomics and metabolomics". Nature chemical biology. Vol. 10, No. 11, pp. 963. (2014).

[53] Clapper, W.E. and G.H. Meade., "Normal flora of the nose, throat, and lower intestine of dogs". Journal of bacteriology. Vol.  85, No. 3, pp. 643-648. (1963).

[54] Dowd, S.E., et al., "Evaluation of the bacterial diversity in the feces of cattle using 16S rDNA bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) ". BMC microbiology. Vol. 8, No. 1, pp. 125. (2008).

 [55] Vargo, D., M. Moskovitz, and M.H. Floch, "Faecal bacterial flora in cancer of the colon". Gut. Vol. 21, No. 8, pp. 701-705. (1980).

[56] Meng, C., et al., "Human gut microbiota and gastrointestinal cancer". Genomics, proteomics & bioinformatics. Vol.  16, No. 1, pp. 33-49. (2018).

[57] Bérdy, J., "Bioactive microbial metabolites". The Journal of antibiotics. Vol. 58, No. 1, pp. 1. (2005).

[58] Newman, D.J. and G.M. Cragg, "Natural products as sources of new drugs over the last 25 years". Journal of natural products. Vol. 70, No. 3, pp. 461-477. (2007).

[59] Olano, C., C. Méndez, and J.A. Salas, "Antitumor compounds from actinomycetes: from gene clusters to new derivatives by combinatorial biosynthesis". Natural product reports. Vol. 26, No. 5, pp. 628-660. (2009).

[60] Invitrogen, G., "Cell culture basics". Life technologies, Gibco. pp. 16-18. (2014).

[61] Gutiérrez-Hoya, A., et al., "Cervical Cancer Cells Express Markers Associated with Immunosurveillance". Journal of immunology research. Vol. 2019, pp. 10-20. (2019).

[62] Lévi, F., et al., "Oxaliplatin". Clinical pharmacokinetics. Vol. 38, No. 1, pp. 1-21. (2000).

[63] Dhillon, S. and L.J. Scott, "Capecitabine". Drugs. Vol. 67, No. 4, pp. 601-610. (2007).

[64] Gallo, R.L. and L.V. Hooper, "Epithelial antimicrobial defense of the skin and intestine". Nature Reviews Immunology. Vol. 12, No. 7, pp. 503. (2012).

[65] Abt, M.C. and E.G. Pamer, "Commensal bacteria mediated defenses against pathogens". Current opinion in immunology. Vol. 29, pp. 16-22. (2014).

[66] Garcia-Gutierrez, E., et al., "Gut microbiota as a source of novel antimicrobials". Gut microbes. Vol. 10, No. 1, pp. 1-21. (2019).

[67] Kaur, S. and S. Kaur, "Bacteriocins as potential anticancer agents". Frontiers in pharmacology. Vol. 6, pp. 272. (2015).

[68] Jiang, Y., et al., "Diversity and bioactivity of cultivable animal fecal actinobacteria". Advances in Microbiology. Vol. 3, No. 01, pp. 1. (2013).

[69] Ding, N., et al., "Bafilomycins and odoriferous sesquiterpenoids from Streptomyces albolongus isolated from Elephas maximus feces". Journal of natural products. Vol. 79, No. 4, pp. 799-805. (2016).

[70] Lee, D.K., et al., "Anti-proliferative effects of Bifidobacterium adolescentis SPM0212 extract on human colon cancer cell lines". BMC cancer. Vol.  8, No. 1, pp. 310. (2008).

[71] López de Felipe, F., B. de Las Rivas, and R. Muñoz, "Bioactive compounds produced by gut microbial tannase: implications for colorectal cancer development". Frontiers in microbiology. Vol. 5, pp. 684. (2014).

[72] Zitvogel, L., et al., "Anticancer effects of the microbiome and its products". Nature Reviews Microbiology. Vol. 15, No. 8, pp. 465. (2017).

[73] Hirayama, K. and J. Rafter, "The role of probiotic bacteria in cancer prevention". Microbes and infection. Vol.  2, No. 6, pp. 681-686. (2000).

View Full Article